Effects of Varying Degrees of Renal Impairment on the Pharmacokinetics of Duloxetine: Analysis of a Single-Dose Phase I Study and Pooled Steady-State Data from Phase II/III Trials - Lobo, Evelyn D.; Heathman, Michael; Kuan, Han-Yi; Reddy, Shobha; O’Brien, Lisa; Gonzales, Celedon; Skinner, Michael; Knadler, Mary Pat (Clinical pharmacokinetics, 2010)
Keywords: Adult; Biological and medical sciences; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug therapy; Duloxetine Hydrochloride; Female; General pharmacology; Humans; Internal Medicine; Kidney Failure, Chronic - blood; Kidney Failure, Chronic - drug therapy; Kidney Failure, Chronic - pathology; Major depressive disorder; Male; Medical sciences; Medicine; Medicine & Public Health; Metabolic Clearance Rate - drug effects; Metabolic Clearance Rate - physiology; Middle Aged; Nephrology. Urinary tract diseases; Nephropathies. Renovascular diseases. Renal failure; Original Research Article; Pharmacokinetics; Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions; Pharmacology. Drug treatments; Pharmacology/Toxicology; Pharmacotherapy; Renal failure; Thiophenes - administration & dosage; Thiophenes - pharmacokinetics; Thiophenes - therapeutic use; United States; Normal Renal Function; Renal Impairment; Stress Urinary Incontinence; Duloxetine; Major Depressive Disorder; Kidney disease; Phase III trial; Human; Urinary system disease; Serotonin; Psychotropic; Single dose; Catecholamine; Reuptake inhibitor; Chemotherapy; Nephropathy; Treatment; Phase II trial; Renal failure; Neurotransmitter; Phase I trial; Antidepressant agent; Norepinephrine; Pharmacokinetics